Several studies have shown that treatment of xenograft cancer models with inhibitors of VEGF or VEGFR2, such as anti-VEGFR2 receptor antibodies and apatinib, can exert a synergistic effect with aPD-1 or aPD-L1 mAbs [24,25,26,27,28,29,30]. This evidence concerns the gene KDR and cancer.